Scinai Immunotherapeutics Ltd. Sponsored ADR SCNI

Scinai Immunotherapeutics concludes PC111 arrangements and redirects capital to NanoAb platform development and CDMO business expansion. Capital reallocation to core NanoAb and CDMO operations moderately shifts company priorities and outlook.

Scinai Immunotherapeutics reports first half 2026 corporate highlights and results, emphasizing growing CDMO momentum. Growing CDMO momentum indicates potential revenue growth from contract services without confirming major strategic shifts.

Scinai Immunotherapeutics reported first quarter 2026 financial results along with updates on CDMO platform expansion and progress on strategic growth initiatives. Quarterly results combined with CDMO expansion and growth initiatives point to moderate influence on operations and market positioning.

Scinai Immunotherapeutics Ltd. (SCNI) announces $2.61 million private placement financing. $2.61 million private placement bolsters cash position for biotech operations but lacks transformative scale.

Scinai Immunotherapeutics completes strategic reorganization, establishing a dedicated CDMO platform and lean R&D structure while outlining 2026 priorities. Reorganization creates a revenue-focused CDMO platform and efficient R&D, significantly altering strategic trajectory and investor outlook.

Scinai Immunotherapeutics reported full-year 2025 results with CDMO revenues doubling year-over-year and strategic expansion via collaboration with Recipharm to enhance biopharmaceutical development and manufacturing capabilities. Doubling CDMO revenues combined with Recipharm collaboration represents major growth and strategic positioning for future performance.

Scinai Immunotherapeutics Ltd. (SCNI) highlighted its expanded Contract Development and Manufacturing Organization (CDMO) platform and immunology pipeline at BIO-Europe Spring 2026. Highlighting expanded CDMO capabilities and immunology pipeline at a major biotech conference signals moderate growth potential and partnership opportunities.

Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI) received a Nasdaq notification for failing to satisfy the minimum bid price requirement, as its closing bid price was below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days, or risk delisting. Nasdaq minimum bid price deficiency notice creates substantial delisting risk, threatening stock liquidity, investor sentiment, and market performance.

Scinai Immunotherapeutics Ltd. (SCNI) signed a second amendment to its PinCell option agreement and submitted a revised €12 million non-dilutive FENG application to advance PC111 through human proof of concept. Amending the PinCell option and pursuing €12 million non-dilutive funding to reach human proof of concept for PC111 represents a major pipeline advancement with strong potential to enhance SCNI's clinical prospects and investor appeal.

Scinai Immunotherapeutics Ltd. announces expanded support from the Israel Innovation Authority for its robotic aseptic fill & finish platform, aimed at advancing biotherapeutic drug production. Expanded Israel Innovation Authority support provides funding and validation for Scinai's core robotic manufacturing technology, significantly enhancing development speed and competitive edge in biopharma.

Scinai Immunotherapeutics Ltd. (SCNI) completed acquisition of Recipharm Israel Ltd. and entered strategic commercial collaboration with Recipharm to accelerate clinical and commercial development of immunology assets. Acquisition completion and strategic collaboration bolster manufacturing capabilities and commercialization pathways, significantly enhancing competitive positioning.

Amir Reichman, CEO of Scinai Immunotherapeutics Ltd., has been appointed to co-lead the Biopharma Manufacturing Roundtable at HealthIL, an initiative aimed at enhancing biopharmaceutical manufacturing in Israel. This roundtable will focus on addressing challenges and promoting collaboration within the biopharma sector, potentially benefiting companies involved in biopharmaceutical production. Participation in the Biopharma Manufacturing Roundtable may enhance Scinai's competitive positioning and innovation in the biopharmaceutical sector.

Scinai Immunotherapeutics Ltd. reported its nine-month 2025 results, highlighting continued growth in its Contract Development and Manufacturing Organization (CDMO) segment and advancements in its NanoAbs pipeline. The company is focusing on expanding its capabilities and product offerings, which are expected to enhance its market position and financial performance moving forward. Significant growth in CDMO and advancements in the NanoAbs pipeline are likely to impact future performance and investor sentiment.

Scinai Immunotherapeutics Ltd. has been awarded a grant from the Israel Innovation Authority to enhance its fill-and-finish contract development and manufacturing organization (CDMO) capabilities. This funding will support the expansion of Scinai's production facilities, enabling the company to better serve its clients in the biopharmaceutical sector and improve its operational efficiency. The grant will significantly enhance Scinai's manufacturing capabilities, potentially improving its competitive position and market performance.

Scinai Immunotherapeutics Ltd. reported its financial results for the first half of 2025, showcasing continued growth in Contract Development and Manufacturing Organization (CDMO) revenue and a strengthened balance sheet. The company highlighted its strategic initiatives aimed at enhancing operational efficiency and expanding its market presence, which contributed to positive financial performance during this period. Continued revenue growth and a strengthened balance sheet indicate significant strategic moves that could alter the company's trajectory.

Scinai Immunotherapeutics Ltd. announced a new peer-reviewed publication that supports its product PC111 as a disease-modifying therapy for pemphigus and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). The publication highlights the potential of PC111 to significantly alter the treatment landscape for these serious autoimmune diseases, providing evidence of its efficacy and safety. This development is expected to enhance the company's position in the market and attract further interest from investors and healthcare professionals. The publication of peer-reviewed data supporting PC111's efficacy is likely to significantly impact Scinai's market position and investor sentiment.

Scinai Immunotherapeutics Ltd. announced that Dr. Roberta Lotti of Pincell Srl received the 'Oscar of Italian Dermatology' for her research on PC111, an anti-Fas Ligand monoclonal antibody. This recognition reinforces Scinai's strategic option agreement to acquire Pincell. PC111 targets soluble Fas Ligand, which plays a critical role in Pemphigus Vulgaris and other severe skin diseases. The research demonstrated PC111's efficacy in blocking blister formation, offering a novel, non-immunosuppressive treatment approach. Scinai's CEO expressed confidence in PC111's potential to transform treatment paradigms and deliver significant clinical and strategic value. The award and research findings significantly enhance the credibility and potential market impact of PC111, a key asset in Scinai's pipeline.

Scinai Immunotherapeutics Ltd. announced new funding and growth in its Contract Development and Manufacturing Organization (CDMO) ahead of the BIO International Convention 2025. The company aims to enhance its capabilities and expand its market presence, positioning itself for future opportunities in the biotechnology sector. New funding and CDMO growth are significant strategic moves that could alter the company's trajectory and investor sentiment.

Scinai Immunotherapeutics Ltd. has received Italian government clearance under the Golden Power regulation for its option to acquire 100% of Pincell S.r.l., an Italian biotechnology company. This regulatory approval removes a major condition for the acquisition, allowing Scinai to move forward with finalizing the transaction, pending customary conditions. Scinai's CEO, Amir Reichman, emphasized that while this is a significant step, the transaction is not yet complete. The acquisition is linked to Pincell's lead candidate, PC111, a monoclonal antibody for severe dermatological conditions, which has received Orphan Drug Designation. Scinai's Polish subsidiary has also applied for a €12 million grant to support PC111's development, with a decision expected by mid-July to early August 2025. The acquisition of Pincell and its lead candidate PC111 could significantly enhance Scinai's product pipeline and market position.

Scinai Immunotherapeutics Ltd. reported strong financial results for Q1 2025, highlighting significant revenue growth from its Contract Development and Manufacturing Organization (CDMO) segment. The company also noted a reduction in cash burn, indicating improved financial management. These developments suggest a positive trajectory for Scinai as it continues to enhance its operational efficiency and revenue generation capabilities. Strong CDMO revenue growth and reduced cash burn indicate significant improvements in financial performance and operational efficiency.

Scinai Immunotherapeutics Ltd. reported its annual financial results for 2024, revealing revenues of $658,000, a significant increase from no revenues in 2023 due to its CDMO business generating income for the first time. R&D expenses rose slightly to $5.6 million, while marketing and administrative expenses decreased to $2.6 million. Financial income surged to $13.5 million, primarily from loan conversion to equity, resulting in a net gain of $4.8 million compared to a net loss of $6.5 million in 2023. As of December 31, 2024, cash and equivalents totaled $1.9 million, down from $4.9 million in 2023. The complete audited financial results are available in the company's Annual Report on Form 20-F filed with the SEC. The increase in revenue and net gain indicates a positive shift in financial performance, though challenges remain.

Scinai Immunotherapeutics Ltd. will host a webinar on May 7, 2025, to discuss PC111, a novel monoclonal antibody drug candidate aimed at treating Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). The webinar will cover the unmet medical needs in these conditions and the drug's development plan. Scinai recently entered a binding option agreement to acquire Italian biotech company Pincell, which has licensed PC111 to Scinai's Polish subsidiary for further development. A grant application for Euro 12 million to support PC111's development has been submitted under the European Funds for a Modern Economy program, with a decision expected in Q3 2025. The acquisition of Pincell and the development of PC111 represent significant strategic moves that could enhance Scinai's product pipeline and market position.

Scinai Immunotherapeutics Ltd. has signed an option agreement to acquire Pincell, a company specializing in rare diseases, along with its innovative antibody aimed at treating severe dermatological conditions. This strategic move is expected to enhance Scinai's portfolio in the dermatology sector and address unmet medical needs in rare diseases. Acquiring Pincell and its novel antibody could significantly enhance Scinai's product offerings and market position in a specialized therapeutic area.

Scinai Immunotherapeutics Ltd. will engage with investors and present its innovative immunology and inflammation (I&I) pipeline, along with its boutique cGMP biologics contract development and manufacturing organization (CDMO), at BIO-Europe Spring 2025. The event may enhance investor interest and visibility, potentially impacting market sentiment and product innovation.

Scinai Immunotherapeutics Ltd. has entered into a $10 million Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. This agreement allows Scinai to sell American Depository Shares (ADSs) to Yorkville over three years, subject to a 9.99% ownership cap. The purchase price will be at a 3% discount to the lowest daily volume-weighted average price during a specified period. Scinai plans to use the proceeds for its NanoAbs programs, CDMO business, and general corporate purposes. The SEPA provides flexibility for capital access without operational restrictions. The SEPA represents a significant strategic move that could enhance Scinai's financial position and operational capabilities.

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences. Participation in key conferences may moderately influence financial performance and competitive positioning.

Scinai Immunotherapeutics establishes U.S. subsidiary Scinai Bioservices Inc. for CDMO business unit, aiming to serve early-stage biotech companies in the U.S. Establishment of U.S. subsidiary for CDMO services can significantly impact Scinai's future growth and market performance by expanding its presence in the U.S. market and catering to the growing demand for CDMO services.

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany, joins Scinai Immunotherapeutics' Scientific Advisory Board. Appointment of a world-class expert in dermatology to the Scientific Advisory Board is expected to significantly impact Scinai's future product innovation and competitive positioning.

Scinai Immunotherapeutics' earnings are not reflective of profitability. The article suggests that the company's earnings may have a significant impact on its future performance.

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, joins Scinai Immunotherapeutics' Scientific Advisory Board. The addition of a former senior executive from a major pharmaceutical company to the advisory board is likely to have a significant impact on Scinai Immunotherapeutics' future strategic direction and market performance.